OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House
With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.
You may also be interested in...
Any movement to advance proposed cosmetics reform legislation could be seen as running counter to President Trump's executive orders earlier this year, which now have FDA centers seeking "broad public comment" on how to achieve "meaningful burden reduction."
CFSAN and other FDA centers ask for "broad public comment" the agency will use "to guide our initial review of our regulations" required in President Trump's January executive order for federal agencies to "evaluate existing regulations and identify those that may merit repeal, replacement, or modification."
Imminent OTC monograph reform legislation signals an agreement between industry and FDA on details of a proposal, which also includes a potential user fee program. CHPA also is hopeful for legislation restoring direct OTC drug purchases with pre-tax savings accounts.